A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Summary

To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)

Timeline

Start

2007-09

Primary completion

2009-12

Completion

2009-12

Drugs

Indications